Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep medicine.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

The Indianapolis-based drugmaker also reaffirmed its 2025 revenue guidance but noted that the calculation was based on ...

Effective July 1, 2025, CVS Caremark will place Wegovy injection 2.4 mg as preferred on its commercial template formularies.

Novo Nordisk has teamed up with Hims & Hers Health, LifeMD and Ro for cash-paying patients to access Wegovy injection 2.4 mg ...

TNX-1700 is in preclinical development for gastric and colorectal cancers ...

Kristen Gryskevich, 51, found weight to be a struggle throughout her life, but when she gave birth to her two boys in 2001 ...

Zepbound (tirzepatide) is a weekly injectable weight-loss medication. It can be purchased online or in person with a valid ...

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...

Drugmaker Eli Lilly (NYSE: LLY) hasn't been exempt from the recent market pullback, but its stock shot higher following the ...

Our analyst team just revealed what they believe are the 10 best stocks to buy right now ... its two leading GLP-1 drugs, Mounjaro and Zepbound, generated a combined $5.4 billion in revenue.

Last quarter alone, its two leading GLP-1 drugs, Mounjaro and Zepbound, generated a combined ... On average, patients who took 12 mg doses lost 11.5 lbs, or 5.8% of their body weight, while ...